VivoSeq
Oncology

Uveal Melanoma

81

Pipeline Programs↗

29

Active Trials↗

34

Companies Involved↗

Uveal Melanoma is a moderately active landscape with 81 programs across 34 companies. The most active players are Iovance Biotherapeutics, Inc., Foghorn Therapeutics Inc., Iconic Therapeutics, Inc.. 3 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

30/100

Mech. Concentration

7/100

Completion Rate

61/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

2 programs

Phase 1F

Foghorn Therapeutics Inc.

1 program

Phase 1I

Iconic Therapeutics, Inc.

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1H

Hebei Senlang Biotechnology Inc., Ltd.

1 program

Phase 1Roche logo

Roche

2 programs

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

61 of 77 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody912%Protein / enzyme34%Cell therapy23%Antibody–drug conjugate11%Peptide11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 98% of 91 pipeline programs.

Analysis

Trial Status

80

clinical trials

Completed28 · 35%
Recruiting19 · 24%
Terminated14 · 18%
Active, not recruiting10 · 13%
Unknown status5 · 6%
Withdrawn4 · 5%

Clinical Trials

Trial Activity

80 trials

Adjuvant Melatonin for Uveal Melanoma
Recruiting·—·Phase 3·NCT05502900·100 enrolled
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Recruiting·—·Phase 3·NCT06519266·40 enrolled
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06121180·32 enrolled
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Recruiting·—·Phase 2·NCT06070012·44 enrolled
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
Recruiting·—·Phase 2·NCT03467516·47 enrolled
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT07276386·18 enrolled
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Recruiting·UUniversity of Miami·Phase 2·NCT06627244·30 enrolled
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Recruiting·GGrupo Español Multidisciplinar de Melanoma·Phase 2·NCT07057596·19 enrolled
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Recruiting·IIDEAYA Biosciences·Phase 3·NCT07015190·520 enrolled
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Recruiting·MModulation Therapeutics, Inc.·Phase 1·NCT05496686·16 enrolled
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Recruiting·UUniversity of Miami·Phase 2·NCT06932757·63 enrolled
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Recruiting·SSt Vincent's Hospital, Sydney·Phase 1·NCT07203391·8 enrolled
Neoadjuvant Tebentafusp for Uveal Melanoma
Recruiting·TThomas Jefferson University·Phase 2·NCT06414590·19 enrolled
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
Recruiting·—·Phase 2·NCT05077280·40 enrolled
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Recruiting·RReplimune Inc.·Phase 2/3·NCT06581406·280 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)